Zalgen is a leading biotechnology company whose dedicated team of scientists are providing significant research, diagnostics, and therapeutic solutions for serious viral infectious diseases. The company is dedicated to developing and deploying medical interventions to save the lives of individuals around the world suffering from these often-overlooked diseases. Since 2011, Zalgen has focused its efforts on targeting neglected and underrepresented human viral infectious diseases, particularly viral hemorrhagic diseases that include the Ebola virus (EBOV) and the Lassa virus (LASV). Currently, the company has applied its expertise in serious viral infectious diseases—pivoting this year to address the SARS CoV-2 pandemic by developing antibody tests.